Cargando…
Humoral and cellular response to the COVID-19 vaccine in immunocompromised children
BACKGROUND: A suboptimal response to the 2-dose COVID-19 vaccine series in the immunocompromised population prompted recommendations for a 3rd primary dose. We aimed to determine the humoral and cellular immune response to the 3rd COVID-19 vaccine in immunocompromised children. METHODS: Prospective...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662120/ https://www.ncbi.nlm.nih.gov/pubmed/36376507 http://dx.doi.org/10.1038/s41390-022-02374-4 |
_version_ | 1784830624229490688 |
---|---|
author | Morgans, Heather A. Bradley, Todd Flebbe-Rehwaldt, Linda Selvarangan, Rangaraj Bagherian, Amber Barnes, Aliessa P. Bass, Julie Cooper, Ashley M. Fischer, Ryan Kleiboeker, Steve Lee, Brian R. LeMaster, Cas Markus, Kelsey Morrison, Stephen Myers, Angela Myers, Doug Payne, Erin Schuster, Jennifer E. Standley, Sarah Wieser, Andrea Warady, Bradley |
author_facet | Morgans, Heather A. Bradley, Todd Flebbe-Rehwaldt, Linda Selvarangan, Rangaraj Bagherian, Amber Barnes, Aliessa P. Bass, Julie Cooper, Ashley M. Fischer, Ryan Kleiboeker, Steve Lee, Brian R. LeMaster, Cas Markus, Kelsey Morrison, Stephen Myers, Angela Myers, Doug Payne, Erin Schuster, Jennifer E. Standley, Sarah Wieser, Andrea Warady, Bradley |
author_sort | Morgans, Heather A. |
collection | PubMed |
description | BACKGROUND: A suboptimal response to the 2-dose COVID-19 vaccine series in the immunocompromised population prompted recommendations for a 3rd primary dose. We aimed to determine the humoral and cellular immune response to the 3rd COVID-19 vaccine in immunocompromised children. METHODS: Prospective cohort study of immunocompromised participants, 5–21 years old, who received 2 prior doses of an mRNA COVID-19 vaccine. Humoral and CD4/CD8 T-cell responses were measured to SARS-CoV-2 spike antigens prior to receiving the 3rd vaccine dose and 3–4 weeks after the 3rd dose was given. RESULTS: Of the 37 participants, approximately half were solid organ transplant recipients. The majority (86.5%) had a detectable humoral response after the 2nd and 3rd vaccine doses, with a significant increase in antibody levels after the 3rd dose. Positive T-cell responses increased from being present in 86.5% to 100% of the cohort after the 3rd dose. CONCLUSIONS: Most immunocompromised children mount a humoral and cellular immune response to the 2-dose COVID-19 vaccine series, which is significantly augmented after receiving the 3rd vaccine dose. This supports the utility of the 3rd vaccine dose and the rationale for ongoing emphasis for vaccination against COVID-19 in this population. IMPACT: Most immunocompromised children mount a humoral and cellular immune response to the 2-dose COVID-19 vaccine series, which is significantly augmented after receiving the 3rd vaccine dose. This is the first prospective cohort study to analyze both the humoral and T-cell immune response to the 3rd COVID-19 primary vaccine dose in children who are immunocompromised. The results of this study support the utility of the 3rd vaccine dose and the rationale for ongoing emphasis for vaccination against COVID-19 in the immunosuppressed pediatric population. |
format | Online Article Text |
id | pubmed-9662120 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group US |
record_format | MEDLINE/PubMed |
spelling | pubmed-96621202022-11-14 Humoral and cellular response to the COVID-19 vaccine in immunocompromised children Morgans, Heather A. Bradley, Todd Flebbe-Rehwaldt, Linda Selvarangan, Rangaraj Bagherian, Amber Barnes, Aliessa P. Bass, Julie Cooper, Ashley M. Fischer, Ryan Kleiboeker, Steve Lee, Brian R. LeMaster, Cas Markus, Kelsey Morrison, Stephen Myers, Angela Myers, Doug Payne, Erin Schuster, Jennifer E. Standley, Sarah Wieser, Andrea Warady, Bradley Pediatr Res Clinical Research Article BACKGROUND: A suboptimal response to the 2-dose COVID-19 vaccine series in the immunocompromised population prompted recommendations for a 3rd primary dose. We aimed to determine the humoral and cellular immune response to the 3rd COVID-19 vaccine in immunocompromised children. METHODS: Prospective cohort study of immunocompromised participants, 5–21 years old, who received 2 prior doses of an mRNA COVID-19 vaccine. Humoral and CD4/CD8 T-cell responses were measured to SARS-CoV-2 spike antigens prior to receiving the 3rd vaccine dose and 3–4 weeks after the 3rd dose was given. RESULTS: Of the 37 participants, approximately half were solid organ transplant recipients. The majority (86.5%) had a detectable humoral response after the 2nd and 3rd vaccine doses, with a significant increase in antibody levels after the 3rd dose. Positive T-cell responses increased from being present in 86.5% to 100% of the cohort after the 3rd dose. CONCLUSIONS: Most immunocompromised children mount a humoral and cellular immune response to the 2-dose COVID-19 vaccine series, which is significantly augmented after receiving the 3rd vaccine dose. This supports the utility of the 3rd vaccine dose and the rationale for ongoing emphasis for vaccination against COVID-19 in this population. IMPACT: Most immunocompromised children mount a humoral and cellular immune response to the 2-dose COVID-19 vaccine series, which is significantly augmented after receiving the 3rd vaccine dose. This is the first prospective cohort study to analyze both the humoral and T-cell immune response to the 3rd COVID-19 primary vaccine dose in children who are immunocompromised. The results of this study support the utility of the 3rd vaccine dose and the rationale for ongoing emphasis for vaccination against COVID-19 in the immunosuppressed pediatric population. Nature Publishing Group US 2022-11-14 /pmc/articles/PMC9662120/ /pubmed/36376507 http://dx.doi.org/10.1038/s41390-022-02374-4 Text en © The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Clinical Research Article Morgans, Heather A. Bradley, Todd Flebbe-Rehwaldt, Linda Selvarangan, Rangaraj Bagherian, Amber Barnes, Aliessa P. Bass, Julie Cooper, Ashley M. Fischer, Ryan Kleiboeker, Steve Lee, Brian R. LeMaster, Cas Markus, Kelsey Morrison, Stephen Myers, Angela Myers, Doug Payne, Erin Schuster, Jennifer E. Standley, Sarah Wieser, Andrea Warady, Bradley Humoral and cellular response to the COVID-19 vaccine in immunocompromised children |
title | Humoral and cellular response to the COVID-19 vaccine in immunocompromised children |
title_full | Humoral and cellular response to the COVID-19 vaccine in immunocompromised children |
title_fullStr | Humoral and cellular response to the COVID-19 vaccine in immunocompromised children |
title_full_unstemmed | Humoral and cellular response to the COVID-19 vaccine in immunocompromised children |
title_short | Humoral and cellular response to the COVID-19 vaccine in immunocompromised children |
title_sort | humoral and cellular response to the covid-19 vaccine in immunocompromised children |
topic | Clinical Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662120/ https://www.ncbi.nlm.nih.gov/pubmed/36376507 http://dx.doi.org/10.1038/s41390-022-02374-4 |
work_keys_str_mv | AT morgansheathera humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren AT bradleytodd humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren AT flebberehwaldtlinda humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren AT selvaranganrangaraj humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren AT bagherianamber humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren AT barnesaliessap humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren AT bassjulie humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren AT cooperashleym humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren AT fischerryan humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren AT kleiboekersteve humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren AT leebrianr humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren AT lemastercas humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren AT markuskelsey humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren AT morrisonstephen humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren AT myersangela humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren AT myersdoug humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren AT payneerin humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren AT schusterjennifere humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren AT standleysarah humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren AT wieserandrea humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren AT waradybradley humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren |